NOTICE

NOTICE is hereby given that the 09TH ANNUAL GENERAL MEETING of the Members of EVOQ REMEDIES PRIVATE LIMITED (Formally known as Salus Life Science And Research Private Limited) will be held on Thursday, 31st December, 2020 at 04:00 P.M. at the registered office of the Company situated at: F-12-A, First Floor, V R Complex, Near Sanathal Cross Road, Santhal Ahmedabad to transact the following businesses:

ORDINARY BUSINESS:

 To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2020, Statement of Profits & Loss and Notes forming part thereto ("Financial Statement") for the year ended on 31st March, 2020 and Report of the Board of Directors and Auditors thereon.

> On behalf of the board For, EVOQ REMEDIES PRIVATE LIMITED (Formally known as Salus Life Science And

Research Private Limited)

DATE: 31.12.2020

PLACE: AHMEDABAD

BHUMISHTH N. PAR

DIRECTOR [DIN: 02516641]

NOTES:

- A member entitled to attend and vote at the meeting is also entitled to appoint a proxy to attend and vote on a poll instead of himself and proxy need not be a member of the company. proxies in order to be effective, must be received by the company at its registered office at least 48 hours before the time of meeting.
- Proxies in order to be effective should be duly completed stamped and signed and must be deposited at the Registered Office of the Company not less than 48 hours before the conclusion of the meeting.
- Members are requested to notify immediately any change in their address to the Company at its Registered Office.
- Members desiring any information as regards accounts are requested to write to the company at least 7 days before the meeting to enable the management to keep the information ready.

EVOQ REMEDIES PRIVATE LIMITED (Formally known as Salus Life Science And Research Private Limited)

[CIN: U51909GJ2019PTC111205]

DIRECTORS' REPORT

To

THE MEMBERS,
EVOQ REMEDIES PRIVATE LIMITED
(Formally known as Salus Life Science And Research Private Limited)

Your directors have pleasure in presenting 9th Annual Report of the Company together with audited statements of accounts for the Period ended on 31st March, 2020.

1. FINANCIAL RESULTS

PARTICULARS	(R					
	F.Y. 2019-20	F.Y. 2018-19				
Revenue from operations	90721169	32500227				
Other income						
Total Income	32500227	32500227				
Total expenses	90717325	32340866				
Profit/(Loss) Before Depreciation	3844	159361				
Less: Depreciation						
Profit/(Loss) Before Tax	3844	159361				
Less: Tax: Current Tax						
Deferred Tax						
Profit for the year	3844	159361				

2. FINANCIAL PERFORMANCE:

During the period under review your Company has made a profit of Rs. 3844/-. Your directors are confident and optimistic of achieving upward growth and achieving much better results in the coming years.

3. DIVIDEND:-

The board of the Company has decided not to transfer any amount to Reserves & Surplus in Balance Sheet.

4. TRANSFER TO RESERVES:

The Company does not propose any amount to be transferred to any Reserves.

5. PRESENT OPERATIONS AND FUTURE PROSPECTS:

Your Company is doing well in its present line of activities and the Board is taking all steps to expand its present business and add value to its shareholders.

6. CHANGE IN NAME OF THE COMPANY:

During the year under review, the Company has changed its name from Salus Life Science And Research Private Limited to **EVOQ Remedies Private Limited** vide Special Resolution passed by the members at their Extra Ordinary General Meeting held on 28.05.2019.

7. SHIFTING OG REGISTSRED OFFICE OF THE COMPANY :

During the year under review, the Company has shifted its registered office from 50, Kantipark Society, Prabhat Chowk, Ghatlodia, Ahmedabad to F-12-A, First Floor, V R Complex, Near Sanathal Cross Road, Santhal Ahmedabad-382210 vide Board Resolution dated 15.04.2019.

8. CHANGE IN NATURE OF BUSSINESS:

During the year under review, the Company has changed its main object vide Special Resolution passed by the members at their Extra Ordinary General Meeting held on 28.05.2019.

9. CHANGE IN SHARE CAPITAL, IF ANY:

During the year under review, there has been no change in Share Capital of the Company.

10. DEPOSITS:

During the year under report, the Company has not accepted any deposits from public within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

11. APPOINTMENT OF STATUTORY AUDITORS:

Pursuant to the provisions of Section 139, 142 and other applicable provisions of the Companies Act, 2013, if any, read with Companies (Audit & Auditors) Rules, 2014, including any statutory enactment or modification thereof,the Company has appointed **M/s J.M. Patel & Bros.,** Chartered Accountants, Ahmedabad having Firm Registration No. 107707W as the Statutory Auditors of the Company at the Annual General Meeting held on 30th September 2019 till the conclusion of Annual General Meeting of the Company to be held in 2023.

Cost Auditors

The Company has not appointed the Cost Auditor as pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Amendment Rules, 2014, the cost audit is not applicable to the Company.

12. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS, OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND PRACTISING COMPANY SECRETARY:

The Auditors' Report to the Shareholders does not contain any qualification. There were no reservations or adverse remarks made by the Auditors in their report.

The provisions relating to submission of Secretarial Audit Report is not applicable to the Company.

12. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTED TO THE CENTRAL GOVERNMENT

During the year under consideration, there were no such instances.

13. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The company has given loans covered under the provisions of section 186 of the Companies Act, 2013. The details of loans given by company during the year are given in the financial statements of the Company.

14. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

There were no contracts made with related parties as defined under Section 188 of the Companies Act, 2013 during the year under review.

15. ANNUAL RETURN:

The extracts of Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 is furnished in **Annexure** "A" and is attached to this Report.

16. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE YEAR UNDER REVIEW:

During the year under review, the Board met 8 (Eight) times. Proper notices were given and the proceedings were properly recorded and signed in the Minutes book as required by the Articles of Association of the Company and the Companies Act, 2013.

17. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THESE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statement relate and the date of this report except the outbreak of corona virus (COVID-19) pandemic causing significant disturbance and slowdown of economic activity. The Companies operations and revenue were impacted due to COVID-19. Considering the continuing uncertainties, the Company will continue to closely monitor any material changes to future economic conditions.

18. DIRECTORS AND KEY MANAGERIAL PERSONNEL

During the year under review, Ms. Komal V. Patel has been appointed as Director w.e.f. 12.04.2019. And Mr. Kartikkumar Hasmukhbhai Patel has resigned as Director w.e.f. 15.04.2019.

After the end of financial year, Ms. Komal V. Patel has resigned from the position of Director w.e.f 17.06.2020. And Ms. Payal N. Patel has been appointed as Director w.e.f. 17.06.2020.

19. RISK MANAGEMENT:

The Company does not have any Risk Management Policy as the elements of risk threatening the Company's existence are very minimal.

20. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES:

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135 (1) of the Companies Act, 2013 and hence it is not required to formulate policy on Corporate Social Responsibility.

21. COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISAM

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 and 7 of the Companies (Meeting of Board and it's powers) Rules, 2013 is not applicable to the Company.

22. NOMINATION & REMUNERATION COMMITTEE POLICY

The provisions of Section 178 (1) of the Companies Act, 2013 relating to constitution of Nomination & Remuneration Committee are not applicable to

the Company. Hence the Company has not devised any policy relating to appointment of Directors, Payment of Managerial Remuneration, Directors Qualification, Positive Attributes, Independence of Directors, and other related matters as provided under Section 178 (3) of the Companies Act, 2013.

23. INTERNAL FINANCIAL CONTROLS:

Adequate internal control systems commensurate with the nature of the Company's business and size and complexity of its operations are in place and have been operating satisfactorily. Internal control systems consisting of policies and procedures are designed to ensure reliability of financial reporting, timely feedback on achievement of operational and strategic goals, compliance with policies, procedure, applicable laws and regulations and that all assets and resources are acquired economically, used efficiently and adequately protected.

24. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS:

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

25. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:

The Company has no subsidiary, joint venture and associate Company.

26. DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of Section 134 (5) of the Companies Act, 2013, the directors would like to state that:

- In the preparation of the annual accounts, the applicable accounting standards have been followed.
- ii. The directors had selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year under review.
- iii. The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- The directors had prepared the annual accounts on a going concern basis.
- the directors had laid proper internal financial controls are in place and that the financial controls are adequate and are operating effectively and

vi. The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

27. <u>DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE</u> <u>COMPANIES</u>

The Company does not have any Subsidiary, Joint Ventures and Associate Companies.

28. ACKNOWLEDGEMENT:

Your Directors wish to thank the investors, company's Bankers & the statutory authorities for the consistent support received from them throughout the year.

On behalf of the board
For, EVOQ REMEDIES PRIVATE LIMITED
(Formally known as Satus by Science And
Research Private Limits)

GUJARAT

DATE: 31.12.2020 PLACE: AHMEDABAD

DIRECTOR

[DIN: 02516641]

FORM NO. MGT-9 EXTRACT OF ANNUAL RETURN

As on the financial year ended on 31/03/2020

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS

i)	CIN	U24230GJ2010PTC059692
ii)	Registration Date	24.02.2010
iii)	Name of the Company	EVOQ REMEDIES PRIVATE LIMITED (Formally known as Salus Life Science And Research Private Limited)
iv)	Category/Sub-Category of the Company	Company limited by Shares Non-Government Company
v)	Address of the Registered office and contact details	F-12-A, First Floor, V R Complex, Near Sanathal Cross Road, Santhal Ahmedabad -382210
vi)	Whether listed company	No
vii)	Name, Address and Contact details of Registrar and Transfer Agent, if any	N.A

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

SN	Name and Description of main		NIC Code of the	% to total turnover of	
	products / services		Product/service	the company	
1	Scientific	Research	and	74909	100%
	Development				

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S. NO	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY / ASSOCIATE				
N.A							

IV. SHAREHOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of S	hares held a of the y	_	nning	No. of	o. of Shares held at the end of the year			% Ch
	Demat	Physical	Total	% of Tota I Shar es	Demat	Physica I	Total	% of Tota I Shar es	an ge dur ing the yea r
A. Promoters									
(1) Indian									
a) Individual/ HUF	-	10000	10000	100	-	10000	10000	100	-
b) Central Govt	-	-	-	-	-	-	-	-	-
c) State Govt(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	-	-	-	-	-	-	-	-	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any other Directors/Rela tives	-	-	-	-	-	-	-	-	-
Sub-total (A) (1):-	_	10000	10000	100	_	10000	10000	100	-
(2) Foreign									
a)NRIs- Individuals	-	-	-	-	-	-	-	-	-
b) Other- Individuals	-	-	-	-	-	-	-	-	-
c) Bodies Corp.	-	-	-	-	-	-	-	-	-
d)Bank/FI	-	-	-	-	-	-	-	_	-
e) Any	-	-	-	-	-	-	-	_	-
Other	-	-	-	-	-	-	-	-	-

Sub-total (A)(2):-	-	-	-	-	-	-	-	-	-
Total Shareholding of Promoter (A)=(A)(1)+(A(2)	-	10000	10000	100	1	10000	10000	100	ı
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt	-	-	-	1	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(1):-	-	-	-	-	-	-	-	-	-
2. Non- Institutions									

a) Bodies Corp.	-	-	-	-	-	-	-	-	-
i) Indian	-	-	-	-	-	-	-	-	-
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals	-	-	-	-	-	-	-	-	-
i) Individual shareholders holding	-	-	-	-	-	-	-	-	-
nominal share capital uptoRs. 1 lakh									
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	-	-	-	-	-	-	-	-	-
c) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(2):-	1	-	-	-	-	-	-	-	1
Total Public Shareholding (B)=(B)(1)+ (B)(2)	-	1	-	-	-	1	1	-	ı
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	-								1
		10000	10000	100	-	10000	10000	100	

ii) Shareholding of Promoters

S N	Shareholder's Name		ding at the g of the yea	r	Share holding at the end of the year			% change
		No. of Shares	% of total Shares of the company	%of Shares Pledge d / encum bered to total shares	No. of Shares	% of total Shar es of the com pany	%of Shares Pledged / encumber ed to total shares	in share holding during the year
1.						99.9		
	Bhumishth N. Patel	5000	50	1	9999	9	-	+49.99
2.	Payal B. Patel	-	-	-	1	0.01	-	+0.01
3.	Kartikkumar	5000	50		-	-		
	Hasmukhbhai Patel			-			-	0

iii) Change in Promoters' Shareholding (please specify, if there is no change)

SI. No.	Particulars	Shareholding a of the year	t the beginning	Cumulative Shareholding during the year		
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company	
	At the beginning of the year Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc): At the end of the year		NO CHA	NGE		
	The time end of the year					

NOTE:

Sr No	Particulars Bhmishth N. Patel	Date	Reason	At the b of the ye Shares	eginning ear %	Cumulat Shareho during t Shares	lding
	As at the beginning of the year	01.04.2019		5000	50%	5000	50%
	Date wise	06.04.2019	Transfer	1000	10%	6000	60%
	increase/decrease	08.04.2019	from	1000	10%	7000	70%
		09.04.2019	Kartikkumar	1000	10%	8000	80%
		10.04.2019		1000	10%	9000	90%
		11.04.2019		999	9.99%	9999	99.99%
	As at the end of the year	31.03.2020		9999	99.99%	9999	99.99%
2.	Payal N. Patel						
	As at the beginning of the year	01.04.2019		-	-		
	Date wise increase/decrease	13.04.2019	Transfer from Kartikkumar	1	0.01%	1	0.01%
	As at the end of the year	31.03.2020		1	0.01%	1	0.01%
3.	Kartikkumar Hasmukhbhai Patel		as at 01.04.20 03.2020 (Tran	_	entioned a	above)	

Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of Shareholding of Directors and Key Managerial Personnel:

SN	Shareholding of each Directors and each Key Managerial Personnel	Shareholding at the beginning of the year No. of % of total		Cumulative Shareholding during the year No. of % of total		
		shares	shares of the company	shares	shares of the company	
1.	Mr. Bhumishth N. Patel					
	At the beginning of the year	5000	50	9999	99.99	
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc): At the end of the year	9999	99.99	9999	99.99	
2.	Ms. Payal B. Patel	3333	33.33	3333	33.33	
	At the beginning of the year	-	-	1	0.01	
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus / sweat equity etc):	-	-	-	-	
	At the end of the year	1	0.01	1	0.01	
3.	Mr. Kartikkumar Hasmukhbhai Patel					
	At the beginning of the year	5000	50	-	-	
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus / sweat equity etc):	-	-	-	-	
	At the end of the year	-	-	-	-	

iv) INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	-	12,400	-	12,400
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	12,400		12,400

Change in Indebtedness during the financial year				
* Addition	-	-	-	-
* Reduction	-	-	ı	-
Net Change	-	-	-	-
Indebtedness at the end of the financial year				
i) Principal Amount	-	12,400	-	12,400
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	12,400	-	12,400

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

SN.	Particulars of Remuneration	Name of M.D/ W.T.D/ Manager	Total Amount
1	Gross salary	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-
2	Stock Option	-	-
3	Sweat Equity	-	-
4	Commission - as % of profit - others, specify	-	-
5	Others, please specify	-	-
	Total (A)	-	-
	Ceiling as per the Act	-	-

B. Remuneration to other directors:

Sr No	Particulars	Name Director	of	other	Total
1.	Independent Directors •Fee for attending board committee meetings •Commission •Others, please specify		-		-
	TOTAL (1)		-		-
2.	O her Non-Executive Directors ·Fee for attending board committee meetings ·Commission		-		-

·Others, please specify		
TOTAL (2)	-	-
TOTAL (1+2)	-	-
Total Managerial Remuneration	-	-
Overall Ceiling as per the Act	-	-

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

SN	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CS	CFO	Total
1	Gross salary	-	-	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-
	(b) Value of perquisites u/s 17(2) Incometax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	others, specify	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	-	-	_

VII. PENALTIES/PUNISHMENT/COMPOUNDINGOFOFFENCES:

Туре	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)		
		A. (COMPANY				
Penalty							
Punishment			NIL				
Compounding							
		B. D	IRECTORS				
Penalty							
Punishment			NIL				
Compounding	1						
	C. OTHER OFFICERS IN DEFAULT						
Penalty	Penalty						
Punishment		NIL					
Compounding							

Independent Auditor's Report

To the Members of

EVOQ REMEDIES PRIVATE LIMITED

Report on the Financial Statements:

We have audited the accompanying financial statements of EVOQ REMEDIES PRIVATE LIMITED ("the Company"), which comprise the Balance Sheet as at 31st March, 2020, and the Statement of Profit and Loss, the Cash Flow Statement for the year ended on that date and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, and profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibility of Management for the Standalone Financial Statements

The Company's Board of Directors is responsionable for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that



are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Report on Other Legal and Regulatory Requirements:

- As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A' statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2. As required by section 143(3) of the Act, we report that:
 - (1) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (2) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - (3) The Balance Sheet, the statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (4) In our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (5) On the basis of written representations received from the directors as on 31 March, 2020, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2020, from being appointed as a director in terms of Section 164(2) of the Act.



- (6) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, is not applicable to the Company; and
- (7) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given
 - a) The Company does not have any pending litigations which would impact its
 - b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

For M/S. J M PATEL & BROS., **Chartered Accountants** FRN .: 107707W

CA JASHWANT M PATEL (PROPERITOR) Membership No.: 030161

Place: Ahmedabad

DATE:

31/12/2020

Annexure - A to the Auditors' Report

The Annexure referred to in paragraph 1 of the Our Report of even date to the members of EVOQ REMEDIES PRIVATE LIMITED on the accounts of the company for the year ended 31st March, 2020.

1)

- a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- b) All the assets have not been physically verified by the management during the year but the company has regular program of verification of its fixed assets which, in our opinion, is reasonable having regard to the size if the company and the nature of its assets. No material discrepancies were noticed on such verification.
- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, company has no immovable property during the year, however sub clause (c) of clause (i) of CARO, 2016 is not applicable.
- 2) According to the information and explanations given to us, the inventory has been physically verified at reasonable intervals during the year by the management. In our opinion, the frequency of verification is reasonable. The discrepancies noticed on verification between the physical stocks and the book records were not material. The discrepancies have been properly dealt with in the books of accounts.
- The Company has not granted any loans, secured or unsecured to the companies, firms or parties covered in the register maintained under section 189 of the Companies Act. Accordingly clause (iii) of CARO, 2016 is not applicable.
- In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- The Company has not accepted any deposits covered the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act. Therefore, clause (v) of CARO, 2016 is not applicable to the company.
- In our opinion and according to the information and explanation given to us, the provision under sub section (I) of section 148 of the companies Act is not applicable to the company. Therefore, clause (vi) of CARO, 2016 is not applicable.
- According to the records of the company, undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Wealth Tax, Service Tax, Custom Duty, Excise Duty, value added tax, cess to the extent applicable and any



other statutory dues have generally been regularly deposited with the appropriate authorities. According to the information and explanations given to us there were no undisputed amounts payable in respect of statutory dues as on 31st of March, 2020 for a period of more than six months from the date they became payable.

- 8) The Company does not have any loans or borrowings from any financial institution, banks, government or debenture holders during the year. Accordingly, clause (viii) of CARO, 2016 is not applicable.
- 9) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, clause (ix) of CARO, 2016 is not applicable.
- According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- 11) According to the information and explanations give to us and based on our examination of the records of the Company, the Company is private limited So, clause (xi) of the CARO, 2016 for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act is not applicable.
- 12) In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, clause (xii) of CARO, 2016 is not applicable.
- According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.



- 15) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into noncash transactions with directors or persons connected with him. Accordingly, clause (xv) of CARO, 2016 is not applicable.
- 16) The Company is not required to be registered under section 45-IA of the Reserve Bank

For M/S. J M PATEL & BROS., **Chartered Accountants** FRN .: 107707W

CA JASHWANT M PATEL (PROPERITOR) Membership No.: 030161

Place: Ahmedabad

DATE:

31/12/2020 101611ARRABME62

Annexure - B to the Auditor's Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of EVOQ REMEDIES PRIVATE LIMITED ("the Company") as of March 31, 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance note on audit of internal financial controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, Internal Financial Controls and, both issued by ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of financial controls over financial reporting included obtaining an understanding of internal and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that;

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company;
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of Internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI).

For M/S. J M PATEL & BROS., **Chartered Accountants** FRN .: 107707W

(PROPERITOR)

Membership No.: 030161

Place: Ahmedabad

DATE:

31/12/2020

AAAABM 862

EVOQ REMEDIES PRIVATE LIMITED CIN. U24230GJ2010PTC059692 F-12/A, V.R.COMPLEX, SANATHAL CROSS ROAD, SANATHAL, AHMEDABAD

Balance Sheet as at 31st March, 2020

Sr. No	rarticulars	Note Number	As at 31/03/ 2020	As at 31/03/2019
	EQUITY AND LIABILITIES	Number		77,00,2019
1				
Total .	Shareholders' funds			
a b	Share capital	1	100,000	
"	Reserves and surplus	2	175,705	100,00
2	Non-current liabilities		275,705	171,86
a	Long-term borrowings			271,86
DE W	Deferred Tax Liability(Net)	3	12,400	12.40
	rox Elability(Net)			12,40
	Current liabilities		12,400	12,40
a	Short-term borrowings			12,70
b	Trade payables	4	0	
C	Other Current Liabilities	5	56,233,786	21,188,27
d	Short-term provisions	6	0	6,00
			56 222 706	
			56,233,786	21,194,27
	ASSETS		56,521,891	21,478,536
	No.			
a	Non-current assets Tangible Fixed assets			
b 1	Deferred Tax Assets		0	
c	Long-term loans and advances		0	
E SICH	and advances		0	
(Current assets		0	
a	Inventories	11		
b	Trade receivables	7	606,198	300,097
C	Cash and cash equivalents	8	47,179,328	12,280,403
d	Short-term loans and advances	9	22,183	188,350
e	Other current assets	10	8,700,100	8,700,100
			14,082	9,586
Sec	TOTAL		56,521,891 56,521,891	21,478,536
366	accompanying notes forming part of the fir	nancial	30,321,891	21,478,536

In terms of our report attached.

For,M/s. J M PATEL & BROS Chartered Accountants

CA JASHWANT M PATEL

(M. NO: 030161) Place : Ahmedabad Date:

31/12/2020

BHUMISHTH PATE

Director PAYAL PATEL

Place : Ahmedabad 31 | 12 | 2020

EVOQ REMEDIES PRIVATE LIMITED CIN. U24230GJ2010PTC059692 F-12/A, V.R.COMPLEX, SANATHAL CROSS ROAD, SANATHAL, AHMEDABAD

Profit and Loss Statement from 1st April, 2019 to the year ended 31st March, 2020 (Amount in Indian Rupees)

	Particulars	Note Number	For the year Ended 31/03/2020	For the year Ended 31/03/2019
I	INCOME:			
	Revenue from operations Less: Excise duty		90721169	3250022
	Other income		90721169	32500227
	Total revenue		00771160	
11	EXPENDITURE: (a) Cost of materials consumed		90721169	32500227
	(b) Purchases of stock-in-trade (c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	11	90771163 (306,101)	32574608 (300,097)
	(d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (q) Other expenses	12	105800.00 1165 0	0.00 2142
	(4) Other expenses	13	145298	64213
	Total expenses		90717325	32340866
ш	Profit / (Loss) before tax		3,844	159,361
IV	Tax expense: (a) Current tax expense for current year (b) (Less): MAT credit (where applicable) (c) Current tax expense relating to prior years (d) Net current tax expense (e) Deferred tax		0 0 0 0	0 0
10.767	Net Tax Expenses		0	0
٧	Profit / (Loss) for the year		3,844	159,361
	Earnings per share Basic & Diluted (in Rs.) See accompanying notes forming part of the financial statements		0.38	15.94

In terms of our report attached. For,M/s. J M PATEL & BROS Chartered Accountants

CA JASHWANT M PATEL

(Proprietor) (M. NO: 030161) Place : Ahmedabad

Date: 31/12/2020

BHUMISHTH PATER

Director PAYAL PATEL

Place : Ahmedabad Date: _

31/12/2020

EVOQ REMEDIES PRIVATE LIMITED CIN. U24230GJ2010PTC059692

6, Rushabh Flat, B/h. Surjan Tower, Nr. Sharda School, Memnagar, Ahmedabad-380052

Notes forming part of Financial Statement

Note 1 : SHARE CAPITAL

(Amount in Indian Rupees) Particulars As at 31/03/2020 As at 31/03/2019 SHARE CAPITAL **Equity Share Capital** Authorised share Capital 2500000 Equity Shares of Rs. 10/- each 100000 100000 Issued, Subscribed and fully paid sh. Capital Equity shares of Rs. 10/- each 100000 Calls Unpaid 100000 Forfeited Shares

0

0

100000

0

Total>>>> 100000

Note 2 : RESERVES & SURPLUS

Particulars	As at 31/03/2020	As at 24/02/2016
Court I D	1 21 2 17 237 20 20	As at 31/03/2019
Capital Reserve		
Securities Premium Reserve	0	0
Surplus / (Deficit) in Statement of P/L Account Opening Balance	0	C
Add Profit or (Loss) for the Year	171861	12500
Amt Transfer from General Reserve	3844	159361
Amt Transfer from Other Reserve	0	139301
Amt Transfer from Other Reserve Less		0
Dividends	o l	0
Amt Transfer to General Reserves	0	0
Amt Transfer to Other Reserves	O O	0
Closing Balance	0	0
Miscellaneous Expenditure	175705	171861
	0	0
Total>>>>	175705	
	1/3/03	171861





Particulars	As at 31/03/2020	As at 31/03/2019
Note 3 : LONG TERM BORROWING		
Particulars	As at 31/03/2020	As at 31/03/2019
Terms Loans		
(a) Secured Loans	0	
(b) Unsecured Loans		
	0	
	0	
oans & Advances from Related Parties (a) Secured Loans		
	0	
(b) Unsecured Loans	12400	1240
	12400	1240
Total>>>>		
AND THE STATE OF T	12400	1240
lote 4 : TRADE PAYABLES		
Particulars	As at 31/03/2020	As at 31/03/2019
(a) Sundry Creditors		
(a) Bills Payable	56233786	2118827
Total >>>>	56233786	2118827
ote 5 : OTHER CURRENT LIABILITIES Particulars	As at 31/03/2020	As at 31/03/2019
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	AS at 3 1/03/2019
Audit Fees Payable	0	6000
Total>>>>	0	6000
Martin Commencer		
ote 6 : SHORT TERM PROVISIONS		
Particulars	As at 31/03/2020	As at 31/03/2019
(a) Unpaid Professional fees		A3 dc 31/03/2019
(a) Unpaid ROC Filing fees	0.00	0.00
Total>>>>	0.00	0.00
te 7 : TRADE RECEIVABLES Particulars		
	As at 31/03/2020	As at 31/03/2019
Trade Receivable	47179328	12280403
Total>>>> ES.PRU	47179328	12280403
TO TO TO THE TOTAL TO THE TOTAL TOTA	7020	12200403

13.03

Particulars	As at 31/03/2020	As at 31/03/2019
Note 8 : CASH & CASH EQUIVALENT		
Particulars	As at 31/03/2020	As at 31/03/2019
(a) Cash on Hand (c) Balance With Bank	9699 12484	31470 156880
Total>>>>	22183	188350

Note 9 : SHORT TERM LOANS & ADVANCES


As at 31/03/2020	As at 31/03/2019
700000	700000
700000	700000
8000100	8000100
8700100	8700100
8700100	8700100
	700000 0 700000 8000100 8700100

Note 10 : OTHER CURRENT ASSETS

Particulars	As at 31/03/2020	As at 31/03/2019
GST Recievable Preliminary Expenses Deferred Tax Asset	10558 3524 0	5529 4057
Total>>>>	14082	9586

Note 11: Changes in inventories of finished goods work-inprogress and Stock-in-Trade

Particulars	As at 31/03/2020	As at 31/03/2019
Opening stock Less- Closing Stock	300097 606198	0 300097
Total>>>>	-306101	-300097





Particulars	As at 31/03/2020	As at 31/03/2019
Note 12 : FINANCIAL COSTS		
Particulars	As at 31/03/2020	As at 31/03/2019
Interest on CC Bank Charges	0 1165	2142


2142

1165

Note 13 : OTHER EXPENSES

Total>>>>>

Particulars	As at 31/03/2020	As at 31/03/2019
Medicine Purchase Legal & Professional charges Audit Fees Expenses Office Expenses Refreshment charges Travelling Expense Preliminary expenses W/off Staff Welfare Exps Repair & Maintenance Exps Stationery & Printing Exps Rounding off	0 15000 0 23429 0 63594 533 18458 14410 9880	0.0 3650 600 622 310 562 53
Total>>>>	-6 145298	64213



NOTE: 1 SIGNIFICANT ACCOUNTING POLICIES

a) BASIS OF PREPARATION OF FINANCIAL STATEMENTS:

These financial statements have been prepared to comply with the Generally Accepted Accounting Principles in India, including the Accounting Standards notified under the relevant provisions of the Companies Act, 2013. The financial statements are prepared on accrual basis under the historical cost convention. The financial statements are presented in Indian Rupees rounded off to the nearest rupees in lakhs, unless wherever specifically mentioned otherwise.

b) USE OF ESTIMATES:

The preparation of financial statement in conformity with Generally Accepted Accounting Principles require management to make estimate and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent liabilities on the date of financial statement. Actual result could differ from those estimates. Any revision to accounting estimates is recognized prospectively in current and future periods.

- c) REVENUE RECOGNITION:
 Sales are net of excise duty.
- d) FIXED ASSETS :

The Gross Block of Fixed Assets is shown at historical cost, which includes taxes and other identifiable direct Expenses, less impairment loss. The cost of fixed assets includes the cost of acquisition including freight, taxes, duties and other identifiable direct expenses, except otherwise specifically excluded and expressed by way of note, attributable to acquisition of assets up to the date the asset put to use.

e) DEPRECIATION :

Depreciation is provided on straight-line method at the rates and in the manner specified in Schedule XII of the Companies Act, 2013.

- f) INVESTMENT Investments are valued at cost
- g) VALUATION OF INVENTORIES:

Items of inventories are measured at lower of cost and net realizable value after providing for obsolescence, if any, except in case of by-products, which are valued at net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads incurred in bringing them to their respective present location and condition.

Independent Auditor's Report

Page 9 of 12

h) EARNING PER SHARE:

Basic earnings per share are calculated by dividing profit for the year attributable to the equity shareholder by weighted average number of equity shares outstanding during the year. The diluted EPS is the same as basic EPS.

i) PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS:

Provisions are recognized in respect of obligations where, based on the evidence available, their existence at the balance sheet date is considered probable.

Contingent liabilities are shown by way of notes to the accounts in respect of obligations where, based on the evidence available, their existence at the Balance Sheet date is considered not probable.

Any contingent asset is not recognized in the Accounts.

j) TREATMENT OF RETIREMENT BENEFITS:

At present there is no eligible employee for payment of Gratuity. Leave encashment payable to employees is provided in the accounts on accrual basis.

k) TAXATION:

Income taxes comprises of current & deferred taxes. Current taxes are measured at the amount expected to be paid to the income tax authorities in accordance with the Income Tax Act, 1961. Deferred income tax reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years. Deferred tax is measured based on the tax rates and the tax laws enacted or substantially enacted at the balance sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

I) BORROWING COSTS

Borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of cost of such asset till such time as the asset is ready period of time to get ready for its intended use or sale. All other borrowing costs are recognized as an expense in the period in which they are incurred.

m) CONTINGENCIES AND EVENTS OCCURRING AFTER THE BALANCE SHEET DATE
All contingencies and events occurring after the Balance Sheet date, which have a material effect
on the financial position of the Company, are considered for preparing the financial statements.



NOTE: 2 Additional Information to the Financial Statements:

- The previous year figures have been regrouped / reclassified, wherever Necessary to confirm with the figures of current year.
- In the opinion of the Board and to the best of their knowledge and belief, the value on realization of the current Assets, Loans and Advances in the ordinary course of the business will not be less than the amount stated in the Balance Sheet.
- 3. Micro and Small Scale Business Enterprises:

The management has initiated the process on identifying enterprises which have been providing goods and services to the company and which qualify under the definition of micro and small enterprises, as defined under Micro, Small and Medium Enterprise Development Act, 2006. Accordingly, the disclosures requirement here under is not furnished.

- 4. Debit & Credit balances of outside parties (Including Debtors, Creditors, Loans Given and Loan taken) appearing in Balance Sheet is subject to confirmation by the respective parties.
- 5. The Company has taken unsecured loans/deposits from Directors Shareholders and other parties as per the stipulations of loan/credit facilities taken from Bank.
- 6. Quantity of inventories is based upon physical verification by the management and valuation is based on details of cost and realizable value (wherever applicable) considering the quality and other relevant factors ascertained by management. The quantities of inventories, sales and purchases are taken based on details worked out from the bills and the stock records maintained by the company (wherever applicable).
- 7. Wherever the sufficient supporting is not available for the expenditure incurred by the company we have relied on the explanations given by the management.

For, M/S. J M PATEL & BROSTEL & BROSTEL & BROSTEL & 10707W	For and on behalf of the Board of EVOQ REMEDIES PRIVATE LIMITED
CA JASHWANT M PATEL Properitor M. No. 030161	MISHTH PATE 13 * 03 PAYAL PATEL (Director)
Place: Ahmedabad Date: 45,700	
UDIN 21030161 AAAABBM&& 28	